The role of parasympathetic mechanisms in the infarct-limiting effect of SGLT2 inhibitor ertugliflozin
M. V. Basalay, S. Arjun, S. M. Davidson, D. M. Yellon
This study investigates how the SGLT2 inhibitor ertugliflozin limits myocardial infarct size and finds that this effect is mediated through parasympathetic activation and M3-cholinoreceptor signaling.
bioRxiv · Oct 1, 2021 · PreprintPhysiology